These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 20471761)

  • 1. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
    Simon JA; Nahum GG; Stanislaw H; Gaines T
    Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S
    Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer: the role of hormone therapy.
    Creasman WT
    Semin Reprod Med; 2005 May; 23(2):167-71. PubMed ID: 15852202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping menopausal hormone therapy: if breast cancer really decreased, why did colorectal cancer not increase?
    Nahum GG; Stanislaw H; Simon JA
    Maturitas; 2012 Apr; 71(4):354-9. PubMed ID: 22300685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response.
    Hartsfield CL; Connelly MT; Newton KM; Andrade SE; Wei F; Buist DS
    J Natl Cancer Inst Monogr; 2005; (35):113-5. PubMed ID: 16287896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice.
    Schonberg MA; Wee CC
    J Womens Health (Larchmt); 2005; 14(6):507-14. PubMed ID: 16115005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK; Governale LA
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
    La Vecchia C
    Breast; 2004 Dec; 13(6):515-8. PubMed ID: 15563861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.